317 related articles for article (PubMed ID: 33143662)
1. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.
Wang L; Fang D; Xu J; Luo R
BMC Cancer; 2020 Nov; 20(1):1059. PubMed ID: 33143662
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
3. Activation of p38 MAPK-regulated Bcl-xL signaling increases survival against zoledronic acid-induced apoptosis in osteoclast precursors.
Tai TW; Su FC; Chen CY; Jou IM; Lin CF
Bone; 2014 Oct; 67():166-74. PubMed ID: 25016096
[TBL] [Abstract][Full Text] [Related]
4. Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
Li M; Wang W; Zhu Y; Lu Y; Wan P; Yang K; Zhang Y; Mao C
Acta Biomater; 2018 Sep; 77():365-379. PubMed ID: 30030174
[TBL] [Abstract][Full Text] [Related]
5. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation.
Hahm ER; Kim SH; Pore SK; Mathan SV; Singh RP; Singh SV
Mol Carcinog; 2024 Feb; 63(2):301-313. PubMed ID: 37921547
[TBL] [Abstract][Full Text] [Related]
7. How zoledronic acid improves osteoporosis by acting on osteoclasts.
Wang B; Zhan Y; Yan L; Hao D
Front Pharmacol; 2022; 13():961941. PubMed ID: 36091799
[TBL] [Abstract][Full Text] [Related]
8. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.
Pietrovito L; Comito G; Parri M; Giannoni E; Chiarugi P; Taddei ML
Curr Cancer Drug Targets; 2019; 19(10):807-816. PubMed ID: 30648509
[TBL] [Abstract][Full Text] [Related]
11. Reactive oxygen species are required for zoledronic acid-induced apoptosis in osteoclast precursors and mature osteoclast-like cells.
Tai TW; Chen CY; Su FC; Tu YK; Tsai TT; Lin CF; Jou IM
Sci Rep; 2017 Mar; 7():44245. PubMed ID: 28281643
[TBL] [Abstract][Full Text] [Related]
12. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.
Kim HJ; Kim HJ; Choi Y; Bae MK; Hwang DS; Shin SH; Lee JY
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909508
[TBL] [Abstract][Full Text] [Related]
13. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Hirbe AC; Roelofs AJ; Floyd DH; Deng H; Becker SN; Lanigan LG; Apicelli AJ; Xu Z; Prior JL; Eagleton MC; Piwnica-Worms D; Rogers MJ; Weilbaecher K
Bone; 2009 May; 44(5):908-16. PubMed ID: 19442620
[TBL] [Abstract][Full Text] [Related]
14. Revival of nitrogen-containing bisphosphonate-induced inhibition of osteoclastogenesis and osteoclast function by water-soluble microfibrous borate glass.
Yuan H; Niu LN; Jiao K; Pei DD; Pramanik C; Li JY; Messer R; Kumar S; Pashley DH; Tay FR
Acta Biomater; 2016 Feb; 31():312-325. PubMed ID: 26678828
[TBL] [Abstract][Full Text] [Related]
15. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate and high glucose levels influence osteoclast differentiation and bone absorption via the AMPK pathway.
Dong W; Qi M; Wang Y; Feng X; Liu H
Biochem Biophys Res Commun; 2018 Nov; 505(4):1195-1202. PubMed ID: 30322621
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.
Yang C; Davis JL; Zeng R; Vora P; Su X; Collins LI; Vangveravong S; Mach RH; Piwnica-Worms D; Weilbaecher KN; Faccio R; Novack DV
Cancer Discov; 2013 Feb; 3(2):212-23. PubMed ID: 23269702
[TBL] [Abstract][Full Text] [Related]
18. Regulation of osteogenesis and osteoclastogenesis by zoledronic acid loaded on biodegradable magnesium-strontium alloy.
Li M; Wan P; Wang W; Yang K; Zhang Y; Han Y
Sci Rep; 2019 Jan; 9(1):933. PubMed ID: 30700724
[TBL] [Abstract][Full Text] [Related]
19. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
[TBL] [Abstract][Full Text] [Related]
20. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
